Trevi Therapeutics, Inc. (TRVI)

2.9700 +0.0300 (+1.02%) As of 10:17AM EDT. Market open.

Trevi Therapeutics, Inc.

195 Church Street
16th Floor
New Haven, CT 06510
United States
203-304-2499
https://www.trevitherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 25

Key Executives

Name	Title	Pay	Exercised	Year Born
Ms. Jennifer L. Good	Co-Founder, CEO, President & Director	835.9k	N/A	1965
Dr. Thomas R. Sciascia M.D.	Co-Founder & Chief Science Officer	551.43k	N/A	1953
Dr. David J. Clark A.F.P.M., M.D., M.R.C.P.	Chief Medical Officer	610.64k	N/A	1965
Ms. Lisa Delfini	Chief Financial Officer	N/A	N/A	1970
Mr. Christopher Galletta	Controller & Chief Accounting Officer	N/A	N/A	1978
Mr. Farrell Simon Pharm.D.	Chief Commercial Officer	N/A	N/A	N/A
Ms. Danine Summers	Vice President of Medical Affairs	N/A	N/A	1958

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Corporate Governance

Trevi Therapeutics, Inc.’s ISS Governance QualityScore as of April 29, 2024 is 8. The pillar scores are Audit: 9; Board: 8; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.